MCTR2

MCTR2 (Maresin conjugate in tissue regeneration 2) is an endogenous specialized pro-resolving mediator (SPM) and a member of the maresin family of sulfido-conjugated lipids. It is biosynthesized from docosahexaenoic acid (DHA) in macrophages via the 12-lipoxygenase pathway, where MCTR1 is converted to MCTR2 by gamma-glutamyl transferase (GGT), and MCTR2 is subsequently converted to MCTR3 by dipeptidases. MCTR2 acts as a functional antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), competing with leukotriene D4 (LTD4) to attenuate pro-inflammatory and bronchoconstrictive responses. It also promotes the resolution of inflammation, stimulates macrophage phagocytosis and efferocytosis, and accelerates tissue repair and regeneration. Preclinical studies have investigated MCTR2 for its potential to resolve inflammation, clear bacterial infections, and suppress breast cancer progression by clearing tumor debris and dampening therapy-induced cytokine storms.

Other names

13-cysteinylglycinyl-14-hydroxy docosahexaenoic acid13R-cysteinylglycinyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-docosahexaenoic acidMaresin conjugate in tissue regeneration 2Maresin conjugates in tissue regeneration 2Maresin sulfido conjugate 2cys-Maresin 2cys-Maresin2cys-Maresin-2